CN101636399B - 可用作plk1抑制剂的取代的嘧啶并二氮杂* - Google Patents

可用作plk1抑制剂的取代的嘧啶并二氮杂* Download PDF

Info

Publication number
CN101636399B
CN101636399B CN2008800088890A CN200880008889A CN101636399B CN 101636399 B CN101636399 B CN 101636399B CN 2008800088890 A CN2008800088890 A CN 2008800088890A CN 200880008889 A CN200880008889 A CN 200880008889A CN 101636399 B CN101636399 B CN 101636399B
Authority
CN
China
Prior art keywords
methyl
mol
tetrahydro
pyrimido
diazepine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2008800088890A
Other languages
English (en)
Chinese (zh)
Other versions
CN101636399A (zh
Inventor
蔡建平
陈少清
崔信洁
乐康
建春·托马斯·陆
彼得·米夏埃尔·沃库利希
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
F Hoffmann La Roche AG
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39415299&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN101636399(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by F Hoffmann La Roche AG, Takeda Pharmaceutical Co Ltd filed Critical F Hoffmann La Roche AG
Publication of CN101636399A publication Critical patent/CN101636399A/zh
Application granted granted Critical
Publication of CN101636399B publication Critical patent/CN101636399B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/18—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
CN2008800088890A 2007-03-22 2008-03-11 可用作plk1抑制剂的取代的嘧啶并二氮杂* Expired - Fee Related CN101636399B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US91935807P 2007-03-22 2007-03-22
US60/919,358 2007-03-22
PCT/EP2008/052847 WO2008113711A1 (en) 2007-03-22 2008-03-11 Substituted pyrimidodiazepines useful as plk1 inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201210030872.3A Division CN102746175B (zh) 2007-03-22 2008-03-11 可用作plk1抑制剂的取代的嘧啶并二氮杂*

Publications (2)

Publication Number Publication Date
CN101636399A CN101636399A (zh) 2010-01-27
CN101636399B true CN101636399B (zh) 2012-04-18

Family

ID=39415299

Family Applications (2)

Application Number Title Priority Date Filing Date
CN2008800088890A Expired - Fee Related CN101636399B (zh) 2007-03-22 2008-03-11 可用作plk1抑制剂的取代的嘧啶并二氮杂*
CN201210030872.3A Expired - Fee Related CN102746175B (zh) 2007-03-22 2008-03-11 可用作plk1抑制剂的取代的嘧啶并二氮杂*

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201210030872.3A Expired - Fee Related CN102746175B (zh) 2007-03-22 2008-03-11 可用作plk1抑制剂的取代的嘧啶并二氮杂*

Country Status (23)

Country Link
US (1) US7517873B2 (enExample)
EP (1) EP2139892B1 (enExample)
JP (1) JP5087640B2 (enExample)
KR (1) KR101157848B1 (enExample)
CN (2) CN101636399B (enExample)
AR (1) AR065794A1 (enExample)
AT (1) ATE524472T1 (enExample)
AU (1) AU2008228303B2 (enExample)
BR (1) BRPI0809088A2 (enExample)
CA (1) CA2680757A1 (enExample)
CL (1) CL2008000785A1 (enExample)
CY (1) CY1112102T1 (enExample)
DK (1) DK2139892T3 (enExample)
ES (1) ES2371832T3 (enExample)
HR (1) HRP20110807T1 (enExample)
IL (1) IL200617A (enExample)
MX (1) MX2009010034A (enExample)
PE (1) PE20120495A1 (enExample)
PL (1) PL2139892T3 (enExample)
PT (1) PT2139892E (enExample)
SI (1) SI2139892T1 (enExample)
TW (1) TWI363629B (enExample)
WO (1) WO2008113711A1 (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2010001677A (es) * 2007-08-15 2010-03-11 Vertex Pharma Derivados de 4-(9-(3,3-difluorociclopentil)-5,7,7-trimetil-6-oxo-6 ,7,8,9-tetrahidro-5h-pirimido[4,5-b][1,4]diazepin-2-ilamino)-3-me toxibenzamida como inhibidores de las proteinas cinasas humanas plk1 a plk4 para el tratamiento de enfermedades proli
US20110201818A1 (en) 2007-09-25 2011-08-18 Takeda Pharmaceutical Company Limited Polo-like kinase inhibitors
PL2205603T3 (pl) * 2007-09-28 2014-07-31 Cyclacel Ltd Pochodne pirymidyny jako inhibitory kinaz białkowych
US20090291938A1 (en) * 2007-11-19 2009-11-26 Takeda Pharmaceutical Company Limited Polo-like kinase inhibitors
TWI490214B (zh) 2008-05-30 2015-07-01 艾德克 上野股份有限公司 苯或噻吩衍生物及該等作為ｖａｐ－１抑制劑之用途
EP2303889A1 (en) * 2008-06-18 2011-04-06 F. Hoffmann-La Roche AG Halo-substituted pyrimidodiazepines as plkl inhibitors
BRPI0923305B1 (pt) 2008-12-09 2019-01-22 Gilead Sciences Inc moduladores de receptores toll-like, seu uso e composição farmacêutica que os compreende
CA2748181C (en) 2009-01-06 2019-07-16 Nathanael S. Gray Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders
TWI483941B (zh) 2009-06-17 2015-05-11 Vertex Pharma 流感病毒複製之抑制劑
SI2477987T1 (en) 2009-09-14 2018-03-30 Gilead Sciences, Inc. MODULATORS TO TOLL OF LIKE RECEPTORS
MX2013006836A (es) 2010-12-16 2013-09-26 Vertex Pharma Inhibidores de la replicacion de los virus de la influenza.
UA118010C2 (uk) 2011-08-01 2018-11-12 Вертекс Фармасьютікалз Інкорпорейтед Інгібітори реплікації вірусів грипу
EP2970317A4 (en) 2013-03-15 2016-11-02 Dana Farber Cancer Inst Inc PYRIMIDODIAZEPINONE COMPOUNDS AND METHOD FOR THE TREATMENT OF DISEASES
BR112016001457A2 (pt) 2013-07-25 2017-08-29 Dana Farber Cancer Inst Inc Inibidores de fatores de transcrição e usos dos mesmos
TWI652014B (zh) * 2013-09-13 2019-03-01 美商艾佛艾姆希公司 雜環取代之雙環唑殺蟲劑
SMT201900450T1 (it) 2013-11-13 2019-09-09 Vertex Pharma Inibitori della replicazione di virus dell’influenza
MX2016006200A (es) 2013-11-13 2016-08-08 Vertex Pharma Metodos para preparar inhibidores de la replicacion de virus de influenza.
JP2017504651A (ja) 2014-01-31 2017-02-09 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド ジアゼパン誘導体の使用
WO2015117053A1 (en) 2014-01-31 2015-08-06 Dana-Farber Cancer Institute, Inc. Diaminopyrimidine benzenesulfone derivatives and uses thereof
ES2930667T3 (es) 2014-07-11 2022-12-21 Gilead Sciences Inc Moduladores de receptores de tipo Toll para el tratamiento de VIH
BR112017002369A2 (pt) 2014-08-08 2017-12-05 Dana Farber Cancer Inst Inc derivados de diazepana e usos dos mesmos
TWI780423B (zh) 2014-09-16 2022-10-11 美商基利科學股份有限公司 類鐸受體調節劑的製備方法
JP2017526730A (ja) 2014-09-16 2017-09-14 ギリアード サイエンシーズ， インコーポレイテッド Ｔｏｌｌ様受容体モジュレーターの固体形態
WO2016183120A1 (en) 2015-05-13 2016-11-17 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
EP3294717B1 (en) 2015-05-13 2020-07-29 Vertex Pharmaceuticals Inc. Methods of preparing inhibitors of influenza viruses replication
EP3307728A4 (en) 2015-06-12 2019-07-17 Dana Farber Cancer Institute, Inc. COMBINATION THERAPY OF TRANSCRIPTION INHIBITORS AND CHINESE INHIBITORS
CN108472300A (zh) 2015-09-11 2018-08-31 达纳-法伯癌症研究所股份有限公司 氰基噻吩并三唑并二氮杂环庚三烯及其用途
AU2016319785C1 (en) 2015-09-11 2021-04-01 Dana-Farber Cancer Institute, Inc. Acetamide thienotriazolodiazepines and uses thereof
KR20180081809A (ko) 2015-11-25 2018-07-17 다나-파버 캔서 인스티튜트 인크. 2가 브로모도메인 억제제 및 그의 용도
EP3440084B1 (en) * 2016-04-07 2022-12-21 Dana-Farber Cancer Institute, Inc. Pyrimido-diazepinone kinase scaffold compounds and methods of treating pi3k-mediated disorders
WO2021061894A1 (en) * 2019-09-27 2021-04-01 Dana-Farber Cancer Institute, Inc. Erk5 degraders as therapeutics in cancer and inflammatory diseases
JP7440940B2 (ja) * 2020-03-27 2024-02-29 オップテラ インコーポレイテッド Ｐｌｋ１の選択的分解誘導化合物
WO2022145989A1 (ko) * 2020-12-31 2022-07-07 (주) 업테라 선택적 plk1 억제제로서의 피리미도디아제핀 유도체
IL310678A (en) * 2021-08-10 2024-04-01 Uppthera Inc A new compound that induces PLK1 degradation
GB202313514D0 (en) 2023-09-05 2023-10-18 Cambridge Entpr Ltd Treatment of inflammatory diseases

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1390220A (zh) * 1999-09-17 2003-01-08 艾博特股份有限两合公司 作为治疗剂的激酶抑制剂
CN1551881A (zh) * 2001-09-04 2004-12-01 ���ָ��Ӣ��ķ�������Ϲ�˾ 新颖二氢喋啶酮,其制备方法及作为药物组合物的用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2652648C (en) * 2006-02-14 2016-10-25 Vertex Pharmaceuticals Incorporated Dihydrodiazepines useful as inhibitors of protein kinases
TW200808325A (en) * 2006-07-06 2008-02-16 Astrazeneca Ab Novel compounds

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1390220A (zh) * 1999-09-17 2003-01-08 艾博特股份有限两合公司 作为治疗剂的激酶抑制剂
CN1551881A (zh) * 2001-09-04 2004-12-01 ���ָ��Ӣ��ķ�������Ϲ�˾ 新颖二氢喋啶酮,其制备方法及作为药物组合物的用途

Also Published As

Publication number Publication date
AR065794A1 (es) 2009-07-01
CL2008000785A1 (es) 2009-03-27
US20080234255A1 (en) 2008-09-25
PT2139892E (pt) 2011-11-21
PE20120495A1 (es) 2012-05-12
US7517873B2 (en) 2009-04-14
PL2139892T3 (pl) 2012-03-30
SI2139892T1 (sl) 2011-12-30
EP2139892B1 (en) 2011-09-14
CY1112102T1 (el) 2015-11-04
HK1139936A1 (en) 2010-09-30
CN102746175B (zh) 2014-01-15
EP2139892A1 (en) 2010-01-06
JP2010521514A (ja) 2010-06-24
WO2008113711A1 (en) 2008-09-25
BRPI0809088A2 (pt) 2014-09-09
TWI363629B (en) 2012-05-11
CN102746175A (zh) 2012-10-24
ATE524472T1 (de) 2011-09-15
JP5087640B2 (ja) 2012-12-05
KR20090119913A (ko) 2009-11-20
DK2139892T3 (da) 2011-12-12
TW200843781A (en) 2008-11-16
IL200617A (en) 2014-02-27
CA2680757A1 (en) 2008-09-25
ES2371832T3 (es) 2012-01-10
CN101636399A (zh) 2010-01-27
KR101157848B1 (ko) 2012-07-11
IL200617A0 (en) 2010-05-17
AU2008228303A1 (en) 2008-09-25
HRP20110807T1 (hr) 2011-12-31
MX2009010034A (es) 2009-10-12
AU2008228303B2 (en) 2012-04-19

Similar Documents

Publication Publication Date Title
CN101636399B (zh) 可用作plk1抑制剂的取代的嘧啶并二氮杂*
CN108697714B (zh) 稠合嘧啶化合物或其盐
CN104854101B (zh) Alk激酶抑制剂
RU2671494C2 (ru) Некоторые ингибиторы протеинкиназы
CN105121443B (zh) 蛋白激酶抑制剂
WO2020207260A1 (zh) 一种cdk激酶抑制剂及其应用
CN107580597A (zh) Pi3k抑制剂的盐及其制备方法
CN113874015B (zh) Ripk2的噻吩并吡啶抑制剂
EP3768272B1 (en) Jak inhibitors
KR20220006104A (ko) 유비퀴틴화 특이적 프로테아제 억제제 및 이의 제조 방법과 응용
WO2022242697A1 (zh) Tyk2选择性抑制剂及其用途
WO2019011228A1 (zh) 咪唑并[1,2-b]嘧啶并[4,5-d]哒嗪-5(6H)-酮类化合物及其应用
WO2022160931A1 (zh) 吡啶并嘧啶类衍生物及其制备方法和用途
KR20210131372A (ko) Syk 억제제로서의 축합된 피라진의 고체 형태
CN114981270B (zh) Mll1抑制剂和抗癌剂
AU2021410926A9 (en) Tetrahydrothienopyrimidinesulfonamide compounds
CN110914273B (zh) 用于治疗糖尿病的作为pde1抑制剂的[1,2,4]三唑并衍生物
TW202423921A (zh) 稠合的雜雙環抗病毒劑
CN115650974B (zh) N-[5-(嘧啶-2-氨基)-2,4-二取代苯基]-顺式戊二烯酰胺衍生物及应用
WO2024240256A1 (zh) 作为激酶抑制剂的多环化合物及其制备方法和用途
WO2024240242A1 (zh) 含有酰胺取代的芳香环的化合物、其药物组合物及用途
HK40003732B (zh) 激活素受体样激酶抑制剂
HK1240216B (zh) 蛋白激酶抑制剂
BR112017018312B1 (pt) Sais de inibidor de pi3k, composições que as compreende, seu uso, processos para seu preparo e método de inibição de uma atividade de uma quinase pi3k

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: TAKEDA PHARMACEUTICAL COMPANY LIMITED.

Free format text: FORMER OWNER: HOFFMAN-LALUOAI CO., LTD.

Effective date: 20100629

C41 Transfer of patent application or patent right or utility model
COR Change of bibliographic data

Free format text: CORRECT: ADDRESS; FROM: BASEL, SWITZERLAND TO: OSAKA, JAPAN

TA01 Transfer of patent application right

Effective date of registration: 20100629

Address after: Osaka

Applicant after: Takeda Chemical Industries, Ltd.

Address before: Basel

Applicant before: F. Hoffmann-La Roche AG

C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20120418

Termination date: 20150311

EXPY Termination of patent right or utility model